Otsuka Pharmaceutical Co. Ltd filed a complaint in the U.S. District Court for the District of New Jersey against Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary, Zydus Pharmaceuticals. The complaint states that Cadila and Zydus’ collaboration on an abbreviated new drug application (ANDA) for the active ingredient in Abilify® infringes an Otsuka patent. Otsuka is seeking to enjoin Zydus and Cadila from marketing or selling a generic Abilify® until their patent expires. Otsuka is represented by Finnegan.